Previously submitted to: JMIR Cardio (no longer under consideration since Oct 01, 2018)
Date Submitted: Apr 4, 2018
Open Peer Review Period: Apr 15, 2018 - Jun 10, 2018
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer-review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer-Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Prevalence of mineralocorticoid antagonist prescription after ST-elevation myocardial infarction with impaired left ventricular function: a single centre experience.
Background:
Evidence suggests long term benefit from angiotensin converting enzyme inhibition (ACE-I) or angiotensin receptor blockade (ARB), beta-adrenoceptor antagonism and mineralocorticoid antagonism (MRA) in patients with left ventricular dysfunction After myocardial infarction. However, despite clinical evidence and clearly articulated guidelines, several studies suggest low rates of prescription of some medications like MRA in the target group with post- myocardial infarction left ventricular dysfunction (MI LVD), both in Australia and other countries
Objective:
To identify the real world medication prescription in ST elevation myocardial infarction (STEMI) patients with impaired left ventricular function
Methods:
We studied prescription trends in 152 consecutive STEMI patients between August 2013 and December 2016 admitted to a single referral centre who also had a pre-discharge echo that demonstrated at least moderate Left ventricular dysfunction
Results:
The average age was 63 years. Most patients were male (78%) and the average BMI was 28 (±6). 132 patients [87% (80% - 92%)] were prescribed ACE-I/ARBs, 144 patients received beta-adrenoceptor antagonists (95% [90% - 98%]), 147 patients (97%) received DAPT and 146 patients (95%) received statins post-STEMI. 45 eligible patients (30% [23% - 28%]) received an MRA. Younger patients were more likely to be prescribed an MRA (p = 0.008). The MRA prescribed cohort were younger, 59 versus 64 years, had marginally better renal function with average eGFR 108 vs 91 mL/min/1.73m2 and lower rates of stage ≥III CKD 11 vs 22 (p <0.05)
Conclusions:
Our study shows a substantial treatment gap, in that a majority of patients with impaired LV dysfunction after STEMI with symptoms of heart failure or diabetes are not receiving medications in the MRA class, despite proven benefit. As such, the root causes of this treatment gap require elucidation in a multi-centre context.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.